Navigation Links
Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Date:12/10/2007

edures while being treated with LOVENOX(R) (enoxaparin sodium injection) or other low-molecular-weight heparins are at risk of developing a blood clot in or around the spine. This condition may result in long-term or permanent paralysis.

LOVENOX(R) is not the same as "unfractionated heparin" or other drugs called "low-molecular-weight heparins." Therefore, these drugs cannot be used interchangeably with LOVENOX(R).

LOVENOX(R) can alter the blood's ability to clot. Patients treated with LOVENOX(R), who also have conditions affecting the clotting system, must be carefully monitored by their physician. Adjusting the dose of LOVENOX(R) may be necessary for patients who have certain forms of kidney disease. All patients receiving LOVENOX(R), as well as other anticoagulants, should be carefully monitored for bleeding by their physician. Bleeding can occur at any site with LOVENOX(R) use.

Platelet drops, known as "thrombocytopenia," can occur with LOVENOX(R) use. Cases of a related condition called "heparin-induced thrombocytopenia" have been observed in clinical practice. If you have had this condition, you must notify your healthcare professional. Your physician may perform blood tests to monitor for the occurrence of any drop in platelet count.

The use of LOVENOX(R) has not been adequately studied in pregnant women with artificial (mechanical) heart valves.

LOVENOX(R) should not be used in patients with an allergy or sensitivity reaction to the active ingredient called enoxaparin sodium, heparin, or pork products, and in patients with active major bleeding.

Common side effects include mild local reactions or irritation at the site of injection, pain, bruising, and redness of skin.

For specific questions about your health, you should always consult your physician or a qualified healthcare professional who is responsible for your care.

Please see Full Prescribing Information including boxed WARNING, for additional im
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  Formex, LLC ("Formex"), a leader in ... Weilersbacher joined Formex as Director of Quality ... Greg Weilersbacher has over 20 ... in Quality Assurance, Facility Validation, GMP manufacturing, and ... to Formex a diverse wealth of experience. ...
(Date:9/16/2014)... 2014 On September 25 to 26, 2014, ... medical design and manufacturing - MEDTEC China  - will ... Exhibition & Convention Center, bringing together close to 300 ... showcase their latest medical-grade raw materials, parts and processing ... remaining for free visitor pre-registration to be completed. To ...
(Date:9/16/2014)... 16, 2014 CorMedix Inc. ("CorMedix") (NYSE ... and commercializing therapeutic products for the prevention and ... the amendment and restatement of its outstanding Series ... related warrants, as well as the warrants issued ... financing, to remove anti-dilution, price reset and certain ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... , , STAMFORD, ... Zargis Medical, a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE ... New Product Awards on February 11th—the 163rd birthday of renowned inventor ... in New York City . Edison created many of the ...
... Rowinsky to Serve on RRD International,s Product Advisory ... 17 RRD International, a strategy-driven biotech and ... Rowinsky , M.D. will oversee oncology product development, serving ...  Dr. Rowinsky is a highly accomplished cancer therapeutics expert ...
Cached Medicine Technology:Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 2Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 3Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International 2Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International 3
(Date:9/16/2014)... therapy and radiation therapy as part of breast ... women with hormone-receptor positive (HR+) invasive breast cancer. ... Cancer Center, however, shows that combination may not ... disease. , The results, which Fox Chase ... Oncology,s 56th Annual Meeting on Sunday, September 14, ...
(Date:9/16/2014)... 2014 Programs and policies that promote ... billions of dollars in savings for the US health ... Fund. To help spur these types of improvements, the ... collaborative groups from across the country to field test ... - a handbook designed to assist groups working together ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Who:, The ... Anschutz Medical Campus and Children’s Hospital Colorado ... is the country’s leading pulmonary hypertension association that works to ... a disease of the lungs that affects the functioning of ... treatment, mean survivability is only 2.8 years. , What:, ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... objective scientific way to diagnose major depression in adults, a ... nine genetic indicators (known as "RNA markers") in the blood. ... cognitive behavioral therapy, one of the most common and effective ... Northwestern University researchers report. Depression affects nearly 7 percent ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, ... U.S. cancer survivors are alive today, compared to just ... Research reported Tuesday. These individuals amount to 4 ... of childhood cancer, according to the association,s annual progress ... and treatment of cancer and details some of the ...
Breaking Medicine News(10 mins):Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... ... to familiarize themselves with the draft of the new Diagnostic and Statistical Manual (DSM), ... mental disorders in children and adults. , ... Arlington, VA (PRWEB) February 12, 2010 -- The National Alliance ...
... , MISSION VIEJO, Calif. , Feb. 12 ... the parent company of the Ensign™ group of skilled nursing, ... today that it expects to issue its fourth quarter and ... Wednesday, February 17, 2010 . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... , PITTSBURGH , Feb. 12 ... launched its free antibiotics program in September of 2009, and ... more than $3 million in free prescriptions for ... more than 590,000 prescriptions for free antibiotics have been filled ...
... , BEAVER, Penn. , Feb. 12 ... UMPS CARE Charities, are proud to announce that the 5th Annual UMPS ... in need. , NNDS and SlateXP are proud to support the ongoing ... umpires. The funds raised at the Golf Classic ensure that umpires will ...
... Feb. 12 Making healthy choices can be a difficult ... Northwest and Intermountain Region continues to support its community by offering ... health care system and rewards for living healthier – all through ... the latter half of 2009, myRegence.com earned 17 key ...
... 12, 2010Hypnosis has potential therapeutic value in children with ... or unexplained sensations of difficulty breathing and for lessening ... hypnosis as an adjunct to conventional treatment and its ... physiological changes are explored in a provocative paper in ...
Cached Medicine News:Health News:NAMI Encourages DSM-5 Discussion 2Health News:The Ensign Group Schedules Year-End 2009 Earnings Call for Thursday, February 18, 2010 2Health News:Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions 2Health News:National Network of Digital Schools, SlateXP and UMPS CARE Raise $75,000 for Children 2Health News:National Network of Digital Schools, SlateXP and UMPS CARE Raise $75,000 for Children 3Health News:Industry Recognizes the Regence Health Engine for Excellence in Creativity, Innovation and Information 2Health News:Industry Recognizes the Regence Health Engine for Excellence in Creativity, Innovation and Information 3Health News:Hypnosis can relieve symptoms in children with respiratory diseases 2
... The QuickLink™ Delivery System ... device designed to assemble ... SourceLink Connectors into seed ... and with variable seed ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
Medicine Products: